Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has appointed Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings more than two decades of neuroscience-focused medical affairs leadership, having held senior roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. His appointment is expected to bolster Helus Pharma's pipeline advancement and strengthen engagement with clinical and scientific stakeholders.
The company, operating under the commercial name Helus Pharma and formerly known as Cybin Inc., is dedicated to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These investigational therapies aim to address the significant unmet need for individuals suffering from depression, anxiety, and other mental health conditions. Helus Pharma's lead candidate, HLP003, is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 trials for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
Dr. Kramer's extensive experience in neuroscience medical affairs is expected to be instrumental as Helus Pharma progresses its clinical programs. His background includes leadership in both early and late-stage drug development, as well as expertise in regulatory interactions and stakeholder communications. The company's focus on NSAs represents a novel approach to mental health treatment, aiming to provide durable improvements through neuroplasticity modulation. With class-leading data, Helus Pharma seeks to improve the treatment landscape for conditions that affect millions worldwide.
For more details on the announcement, visit the full press release at https://ibn.fm/FdEXH. Updates on Helus Pharma's progress are available at their website www.helus.com and through their newsroom at https://ibn.fm/HELP. The company operates in Canada, the United States, the United Kingdom, and Ireland.
